Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.

As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and ...

Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...

Lentiviral vectors are one of the foundational technologies of cell and gene therapy. Along with adenoviral vectors, they are one of the most widely used means of introducing genetic information into ...

GERMANTOWN, MD / ACCESS Newswire / March 30, 2026 /uBriGene Biosciences, a leading global CDMO specializing in lentiviral ...

LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy ...

Lentiviral vectors effectively deliver the gene that encodes coagulation factor IX (FIX) to the liver in dogs with naturally occurring hemophilia B (factor IX deficiency), researchers report in an ...

On 25 March, detailed Phase I trial data was published for ESO-T01, AstraZeneca’s in vivo CAR-T therapy, in patients with multiple myeloma (MM) who have been treated with at least three previous ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with ...